Trial Profile
Randomized, Double-blind, Placebo-controlled, Multiple-dose, Exploratory Proof of Concept Study to Assess the Safety, Tolerability, Efficacy, Pharmacodynamic (PD) and Pharmacokinetics of QAX576 in Patients With Rapidly Progressive IPF
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 01 Jul 2014
Price :
$35
*
At a glance
- Drugs Dectrekumab (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Novartis Pharmaceuticals Corporation
- 01 Jul 2014 New trial record